Single center study of 47 RA-ILD pts (Dx Age 64.7 yrs; 30 mos F/U). Median 100 mos from RA Dx to RA-ILD. Nearly half (49%) recv Rx for RA-ILD; few w/ TCZ, nintedanib, pirfenidone. ~90% had RA-ILD stability/improve @ 6 & 12 mos. Progression assoc w/ tobacco use (P .025) @ 6 mos https://t.co/AK4zYgcxeK

Regional Disparities in DMARD Management for RA Treatment Dr. Aurelie Najm, Glasgow, reports on a session on "Updates on DMARDs treatment: global standards and regional adaptations" from the APLAR 2025 Congress in Fukuoka, Japan. https://t.co/zDo5NxKtbE https://t.co/kF9FxyWkIQ

• Regional Disparities in DMARD Management for RA Treatment | RheumNow

Italian Systemic sclerosis (SPRING-SIR) registry - 1157/1538 (75%) SSc pts were in menopause, 632 (50%) had pre-menop SSc onset, 130 (14.4%) had early menopause. Post-menop. had more CREST, centromere Abs, ILD & GI Sxs. Pre-menop. had more diffuse Dz & peripheral vasculopathy. https://t.co/Jz2v5CkH0Y

ERS/EULAR guidelines for CTD-related interstitial lung disease The European Respiratory Society (ERS) and European Alliance of Associations for Rheumatology (EULAR) have released clinical practice guidelines for evaluating and managing connective tissue diseases (CTD) https://t.co/2mmxsor4ND

COLCHICORT Trial The COLCHICORT trial in acute calcium pyrophosphate (CPP) crystal arthritis patients showed that colchicine was inferior to prednisone treatment and that responses were also influenced by other factors. https://t.co/CC2yVRXbD5 https://t.co/ebLa3FUbGR

• COLCHICORT Trial | RheumNow

A new player in AIRD ThA age associated T helper cells Displaying both Cytotoxic & APC functions Correlation with disease activity in RA and SLE More research is needed to better characterize function but could be a promising therapeutic target @RheumNow #APLAR25 https://t.co/4SnY65tXpJ

• https://x.com/AurelieRheumo/status/1964216189477093887/photo/1

What to give next? Bone sequencing therapy provides a novel perspective in #osteoporosis treatment. Several sequential approaches exist. Better treatment plan = better patient outcomes #APLAR25 @RheumNow @rheumarhyme https://t.co/XvwnT9ZCU2

• https://x.com/RHEUMarampa/status/1964173064020906074/photo/1
• https://x.com/RHEUMarampa/status/1964173064020906074/photo/1
• https://x.com/RHEUMarampa/status/1964173064020906074/photo/1

This slide reflects the rheumatologist’s goals for treating #lupus Prof. Mosca also highlights the fact that achieving targets is as important as maintaining these treatment targets. @RheumNow #APLAR25 https://t.co/u8fw3fThXI

• https://x.com/RHEUMarampa/status/1964141957275644392/photo/1

Prof. Eric Morand on the SLE T2T approach. Ultimate goal is remission but we know that not all patients achieve this state. Thru the T2T approach, low dse activity (LLDAS) is an acceptable target & a protective alternative goal @RheumNow #APLAR25 #Lupus https://t.co/vz7E5prps0

• https://x.com/RHEUMarampa/status/1964138189842415720/photo/1

Optimizing outcomes of pregnancy in #lupus: 📌 all patients should undergo preconception counselling 📌 close monitoring by a multidisciplinary team - a ⬇️ cerebroplacental ratio reflects placental dysfunction #APLAR25 @RheumNow @rheumarhyme https://t.co/RSyqgpRTG5

• https://x.com/RHEUMarampa/status/1963886577081581728/photo/1
• https://x.com/RHEUMarampa/status/1963886577081581728/photo/1

@Lupusreference reviews clinical trials in LES, highlights key limitations of current outcome measures and propose a novel a clinical outcome in SLE based on « How patients feel function and survive » Very relevant to the human experience of having a chronic illness @RheumNow https://t.co/vM58C9KfQ3

• https://x.com/AurelieRheumo/status/1963879956930568311/photo/1

Controversies in ILD Join leading experts as they tackle complex topics: IPAF, MTX, SARD vs. CTD, and anti-fibrotic therapy. 📅 Sep 16, 2025 | ⏰ 7 PM ET Jeffrey Sparks, MD | Janet Pope, MD | Elena Joerns, MD Moderator: Jack Cush, MD 👉 Register: https://t.co/O4FQNyGeTr https://t.co/jIfjuWWNvp

• Welcome! You are invited to join a webinar: Controversies in ILD. After registe…

🆕 Intro to ILD (Part I): the essentials 🫁 Definition & basics 🔬 Key pathology patterns 🧑⚕️ Clinical approach 📋 What rheums need to know ⬇️ Download & learn more: https://t.co/Fn76PiGsPl Created by @MithuRheum | via @RheumNow for our Rheum to Breathe: ILD Campaign https://t.co/MalDKUjonR

• ILD: Background/Introduction (Part One) | RheumNow